06/12/2026
Anktiva is an immunotherapy linked to Patrick Soon-Shiong’s work in developing cancer treatments that activate the body’s own immune defenses.
Instead of working like traditional chemotherapy, this approach focuses on stimulating immune cells that can recognize and attack abnormal or cancerous cells.
Natural killer cells are part of the immune system’s first line of defense and are being studied for their role in targeting tumors more precisely.
Immunotherapy has become one of the most important areas in modern cancer research because it may help some patients respond when older treatments are limited.
The treatment still depends on cancer type, medical approval, patient condition, and clinical evidence, but it highlights how cancer care is moving toward more targeted immune-based strategies.